<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Apoptotic deletion of expanded B cell populations is essential in avoidance of <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> and immune regulation of some B cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The role of CD4+ T cells in B cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> is evident from the high incidence of B cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and <z:hpo ids='HP_0002960'>autoimmunity</z:hpo> in patients with T cell diseases such as the acquired <z:hpo ids='HP_0002721'>immune deficiency</z:hpo> syndrome (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>We have previously demonstrated that in Epstein-Barr Virus (EBV) negative Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> derived from proliferating centroblasts of the germinal center, the malignant lymphocytes can be induced to express Fas (CD95) by ligation of CD40 at the B cell surface </plain></SENT>
<SENT sid="3" pm="."><plain>Upon CD40 engagement, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells are sensitized to T-cell derived <z:hpo ids='HP_0011420'>death</z:hpo> signals provided by Fas ligand (FasL, CD95L) </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HBL</z:e>-3 is a cell line derived from an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> in which the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> IgM binds the human erythrocyte "i" antigen </plain></SENT>
<SENT sid="5" pm="."><plain>To determine whether Fas-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells is reduced in the context of antigen to which the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> IgM binds, we stimulated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HBL</z:e>-3 cells with CD40 ligand (CD40L, CD154) in the presence and absence of human erythrocytes expressing the "i" antigen, and measured Fas-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> upon exposure to an agonistic anti-Fas antibody </plain></SENT>
<SENT sid="6" pm="."><plain>We observed that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HBL</z:e>-3 cells were sensitized to Fas-mediated <z:hpo ids='HP_0011420'>death</z:hpo> by exposure to CD40L </plain></SENT>
<SENT sid="7" pm="."><plain>When i+ RBCs were present, Fas-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HBL</z:e>-3 cells was reduced by greater than 30% </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, there was no reduction in Fas-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in the presence of i- (I+) RBCs </plain></SENT>
<SENT sid="9" pm="."><plain>These findings demonstrate that Fas-mediated deletion of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells is inhibited upon surface IgM engagement by antigen for which the malignant clone has affinity </plain></SENT>
</text></document>